Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:602537.
doi: 10.1155/2010/602537. Epub 2010 Feb 7.

Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients

Alfredo Halpern  1 , Renata B Pepe, Ana Paola Monegaglia, Mônica Beyruti, Maria Edna de Melo, Marcio C Mancini
Affiliations

Efficacy and tolerability of the association of sibutramine and orlistat for six months in overweight and obese patients

Alfredo Halpern et al. J Obes. 2010.

Abstract

Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 months. Results. After 3 months, the mean weight loss was 10.5 kg (-9.8% of the initial weight, n = 263), and after 6 months, the mean weight loss was 13.9 kg (-12.8% of the initial weight, n = 97). The tolerability of such association was quite acceptable and coherent with the action mechanism of each component. Conclusions. The association of orlistat and sibutramine is quite efficient and it seems to promote a higher rate of weight loss than that reported in clinical studies performed with each drug separately.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Weight loss of 446 patients in 3 and 6 months (LOCF).
Figure 2
Figure 2
Evolution of weight loss in 3 and 6 months for patients who completed the study.
Figure 3
Figure 3
Categorical analysis of weight loss (>5% and >10%) in 3 and 6 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Seidell JC. Obesity in Europe: scaling an epidemic. International Journal of Obesity. 1995;19(supplement 3):S1–S4. - PubMed
    1. Pi-Sunyer FX. Medical hazards of obesity. Annals of Internal Medicine. 1993;119(7, part 2):655–660. - PubMed
    1. Bray GA. Health hazards of obesity. Endocrinology and Metabolism Clinics of North America. 1996;25(4):907–919. - PubMed
    1. Thomas PR, editor. Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC, USA: National Academy Press; 1996. - PubMed
    1. Yanovski SZ. Long-term pharmacotherapy in the management of obesity. Journal of the American Medical Association. 1996;276(23):1907–1915. - PubMed

LinkOut - more resources